Drug Trial Radar · NCT01175590
Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
Last checked: Nov 20, 2026Latest source record: May 1, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
518
Actual
Start
Jun 2010
Primary completion
Dec 2011
Study completion Feb 2012
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.
Conditions
- Bacterial Conjunctivitis
Interventions
BesivanceDrug
Ocular administration to affected eye for 7 days
VehicleDrug
Vehicle of Besivance administered to affected eye for 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular Treatment Emergent Adverse EventsTime frame: At each visit - 7 days
- Non-Ocular Treatment-Emergent Adverse EventsTime frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb, Inc.
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.